BridgeBio Pharma, Inc. announced a private placement led by returning investor Cormorant Asset Management, LP and co-led by new investor Omega Fund Management, LLC for the gross proceeds of $200,000,000 on May 2, 2024. The transaction also included participation from new investors Deerfield Management Company, L.P. Series C, GV Management Company, LLC, EcoR1 Capital, LLC, Wellington Management Group LLP, Enavate Sciences, Surveyor Capital Management, Casdin Capital, LLC, Longwood Fund and returning investor Aisling Capital LLC. The transaction was oversubscribed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.12 USD | -6.42% | -2.52% | -32.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.82% | 5.08B | |
-0.33% | 90.59B | |
-0.92% | 38.99B | |
-9.57% | 34.09B | |
-17.98% | 15.02B | |
-6.74% | 13.17B | |
-9.76% | 11.88B | |
-47.31% | 10.65B | |
+6.52% | 9.25B | |
+137.06% | 9.02B |
- Stock Market
- Equities
- BBIO Stock
- News BridgeBio Pharma, Inc.
- BridgeBio Pharma, Inc. announced that it has received $200 million in funding from a group of investors